|
1
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gelsi-Boyer V, Orsetti B, Cervera N,
Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier
C, Monville F M, et al: Comprehensive profiling of 8p11-12
amplification in breast cancer. Mol Cancer Res. 3:655–667. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Normanno N, Bianco C, Strizzi L, Mancino
M, Maiello MR, De Luca A, Caponigro F and Salomon DS: The ErbB
receptors and their ligands in cancer: An overview. Curr Drug
Targets. 6:243–257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Troyer KL and Lee DC: Regulation of mouse
mammary gland development and tumorigenesis by the ERBB signaling
network. J Mammary Gland Biol Neoplasia. 6:7–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DiGiovanna MP, Stern DF, Edgerton SM,
Whalen SG, Moore D II and Thor AD: Relationship of epidermal growth
factor receptor expression to ErbB-2 signaling activity and
prognosis in breast cancer patients. J Clin Oncol. 23:1152–1160.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wrba F, Reiner A, Ritzinger E, Holzner JH
and Reiner G: Expression of epidermal growth factor receptors
(EGFR) on breast carcinomas in relation to growth fractions,
estrogen receptor status and morphological criteria. An
immunohistochemical study. Pathol Res Pract. 183:25–29. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suo Z, Risberg B, Kalsson MG, Willman K,
Tierens A, Skovlund E and Nesland JM: EGFR family expression in
breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different
effects on survival. J Pathol. 196:17–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nieto Y, Nawaz F, Jones RB, Shpall EJ and
Nawaz S: Prognostic significance of overexpression and
phosphorylation of epidermal growth factor receptor (EGFR) and the
presence of truncated EGFRvIII in locoregionally advanced breast
cancer. J Clin Oncol. 25:4405–4413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koletsa T, Kotoula V, Karayannopoulou G,
Nenopoulou E, Karkavelas G, Papadimitriou CS and Kostopoulos I:
EGFR expression and activation are common in HER2 positive and
triple-negative breast tumours. Histol Histopathol. 25:1171–1179.
2010.PubMed/NCBI
|
|
12
|
Hwangbo W, Lee JH, Ahn S, Kim S, Park KH,
Kim CH and Kim I: EGFR gene amplification and protein expression in
invasive ductal carcinoma of the breast. Korean J Pathol.
42:107–115. 2013. View Article : Google Scholar
|
|
13
|
Bhargava R, Gerald WL, Li AR, Pan Q, Lal
P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer:
Correlation with epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activating
mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Normanno N, Bianco C, De Luca A, Maiello
MR and Salomon DS: Target-based agents against ErbB receptors and
their ligands: A novel approach to cancer treatment. Endocr Relat
Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Azambuja E, Procter MJ, van Veldhuisen
DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith
IE, Gianni L, Baselga J, et al: Trastuzumab-associated cardiac
events at 8 years of median follow-up in the Herceptin Adjuvant
trial (BIG 1–01). J Clin Oncol. 32:2159–2165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Graus-Porta D, Beerli RR, Daly JM and
Hynes NE: ErbB-2, the preferred heterodimerization partner of all
ErbB receptors, is a mediator of lateral signaling. EMBO J.
16:1647–1655. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Worthylake R, Opresko LK and Wiley HS:
ErbB-2 amplification inhibits down-regulation and induces
constitutive activation of both ErbB-2 and epidermal growth factor
receptors. J Biol Chem. 274:8865–8874. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Andre F, Job B, Dessen P, Tordai A,
Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, et al:
Molecular characterization of breast cancer with high-resolution
oligonucleotide comparative genomic hybridization array. Clin
Cancer Res. 15:441–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elsheikh Elbauomy S, Green AR, Lambros MB,
Turner NC, Grainge MJ, Powe D, Ellis IO and Reis-Filho JS: FGFR1
amplification in breast carcinomas: A chromogenic in situ
hybridisation analysis. Breast Cancer Res. 9:R232007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reis-Filho JS, Simpson PT, Turner NC,
Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K,
Dexter T, et al: FGFR1 emerges as a potential therapeutic target
for lobular breast carcinomas. Clin Cancer Res. 12:6652–6662. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Penault-Llorca F, Bertucci F, Adélaïde J,
Parc P, Coulier F, Jacquemier J, Birnbaum D and deLapeyrière O:
Expression of FGF and FGF receptor genes in human breast cancer.
Int J Cancer. 61:170–176. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Forozan F, Veldman R, Ammerman CA, Parsa
NZ, Kallioniemi A, Kallioniemi OP and Ethier SP: Molecular
cytogenetic analysis of 11 new breast cancer cell lines. Br J
Cancer. 81:1328–1334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turner N, Pearson A, Sharpe R, Lambros M,
Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A,
et al: FGFR1 amplification drives endocrine therapy resistance and
is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baird K, Davis S, Antonescu CR, Harper UL,
Walker RL, Chen Y, Glatfelter AA, Duray PH and Meltzer PS: Gene
expression profiling of human sarcomas: Insights into sarcoma
biology. Cancer Res. 65:9226–9235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tenhagen M, van Diest PJ, Ivanova IA, van
der Wall E and van der Groep P: Fibroblast growth factor receptors
in breast cancer: Expression, downstream effects, and possible drug
targets. Endocr Relat Cancer. 19:R115–R129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hammond ME, Hayes DF, Wolff AC, Mangu PB
and Temin S: American society of clinical oncology/college of
american pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Oncol Pract. 6:196–197. 2010. View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Russell PA, Yu Y, Young RJ, Conron M,
Wainer Z, Alam N, Solomon B and Wright GM: Prevalence, morphology,
and natural history of FGFR1-amplified lung cancer, including
squamous cell carcinoma, detected by FISH and SISH. Mod Pathol.
27:1621–1631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cihoric N, Savic S, Schneider S, Ackermann
I, Bichsel-Naef M, Schmid RA, Lardinois D, Gugger M, Bubendorf L,
Zlobec I and Tapia C: Prognostic role of FGFR1 amplification in
early-stage non-small cell lung cancer. Br J Cancer. 110:2914–2922.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Courjal F, Cuny M, Simony-Lafontaine J,
Louason G, Speiser P, Zeillinger R, Rodriguez C and Theillet C:
Mapping of DNA amplifications at 15 chromosomal localizations in
1875 breast tumors: Definition of phenotypic groups. Cancer Res.
57:4360–4367. 1997.PubMed/NCBI
|
|
33
|
Kersting C, Tidow N, Schmidt H, Liedtke C,
Neumann J, Boecker W, van Diest PJ, Brandt B and Buerger H: Gene
dosage PCR and fluorescence in situ hybridization reveal low
frequency of egfr amplifications despite protein overexpression in
invasive breast carcinoma. Lab Invest. 84:582–587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhargava R, Gerald WL, Li AR, Pan Q, Lal
P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer:
Correlation with epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activating
mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iqbal N and Iqbal N: Human epidermal
growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
